Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront enzalutamide with PSMA PET/CT response assessment in newly diagnosed metastatic prostate cancer
NL-OMON51572Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by University Medical Center Utrecht. Started Mar 2023; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON51572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51572.